Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.

Antimicrobial Agents and Chemotherapy
K L HeimG R Matzke

Abstract

The disposition of cefotaxime (CTX) and desacetyl cefotaxime (DAC) was studied in eight noninfected patients on continuous ambulatory peritoneal dialysis. Each patient received a single intravenous (i.v.) infusion and an intraperitoneal (i.p.) instillation of 2 g of CTX. Multiple blood and dialysate samples were collected during the 72-h period after drug administration. The half-life, steady-state volume of distribution, and total body clearance of CTX following i.v. administration were 2.2 +/- 1.0 h (mean +/- standard deviation), 0.17 +/- 0.03 liters/kg, and 81.0 +/- 31.0 ml/min, respectively. No significant differences were observed in these parameters after i.p. administration. The continuous ambulatory peritoneal dialysis clearances of CTX and DAC were 1.82 +/- 0.43 and 2.84 +/- 0.70 ml/min, respectively, after i.v. administration. The bioavailability of CTX after i.p. instillation was 74.6 +/- 21.3%. Peak peritoneal dialysate CTX and DAC concentrations of 264.3 and 25.8 mg/liter, respectively, were observed after i.p. dosing. Administration (i.v.) of 2 g every 12 h or i.p. instillation of 2 g every 24 h may be used for the treatment of i.p. infections with highly susceptible organisms (MIC less than 1.0 microgram/ml).

References

Jul 1, 1985·Clinical Pharmacology and Therapeutics·G R MatzkeW F Keane
Sep 1, 1985·Clinical Pharmacology and Therapeutics·H C AlbinC Martin-Dupont
Sep 1, 1980·The Journal of Antimicrobial Chemotherapy·J ChamberlainJ McEwen
Apr 1, 1981·Antimicrobial Agents and Chemotherapy·R WiseP J Wills
Sep 1, 1982·Reviews of Infectious Diseases·R N Jones, C Thornsberry
Aug 1, 1983·Antimicrobial Agents and Chemotherapy·E D Burgess, A D Blair
Jan 1, 1983·Clinical Pharmacology and Therapeutics·C M BunkeF C Luft
Mar 1, 1982·Reviews of Infectious Diseases·H C Neu
Mar 1, 1982·Journal of Pharmaceutical Sciences·D Perrier, M Mayersohn

❮ Previous
Next ❯

Citations

May 1, 1995·Diagnostic Microbiology and Infectious Disease·K Andrassy
Jan 27, 2009·The Journal of Antimicrobial Chemotherapy·Philippe SeguinYannick Mallédant
Jan 7, 1999·The Annals of Pharmacotherapy·N V DahlR A Sherman

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.